Is OCT a Viable Tool to Monitor Disease-Modifying Treatments in RRMS Yet?

Toosy, Ahmed T; Kapur, Kush; Nair, Kavita V

Toosy, Ahmed T; Kapur, Kush; Nair, Kavita V.

Afiliación

Toosy AT; From the Queen Square MS Centre (A.T.T.), Department of Neuroinflammation, UCL Institute of Neurology, Queen Square, London, UK; Department of Neurology (K.K.), Boston Children's Hospital, Harvard Medical School, MA; and Department of Neurology and Pharmacy (K.V.N.), University of Colorado Anschutz Medical Campus, Aurora. a.toosy@ucl.ac.uk.
Kapur K; From the Queen Square MS Centre (A.T.T.), Department of Neuroinflammation, UCL Institute of Neurology, Queen Square, London, UK; Department of Neurology (K.K.), Boston Children's Hospital, Harvard Medical School, MA; and Department of Neurology and Pharmacy (K.V.N.), University of Colorado Anschutz Medical Campus, Aurora.
Nair KV; From the Queen Square MS Centre (A.T.T.), Department of Neuroinflammation, UCL Institute of Neurology, Queen Square, London, UK; Department of Neurology (K.K.), Boston Children's Hospital, Harvard Medical School, MA; and Department of Neurology and Pharmacy (K.V.N.), University of Colorado Anschutz Medical Campus, Aurora.

Neurology ; 96(20): 927-928, 2021 05 18.

Article en En | MEDLINE | ID: mdl-33827959

Asunto(s)

Esclerosis Múltiple Recurrente-Remitente; Esclerosis Múltiple; Degeneración Retiniana; Atrofia; Humanos; Rituximab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Degeneración Retiniana / Esclerosis Múltiple Recurrente-Remitente / Esclerosis Múltiple Límite: Humans Idioma: En Revista: Neurology Año: 2021 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google